Magle PharmaCept announces participation in the ET2024 Congress, in Vienna

At Magle PharmaCept, we are excited to announce our participation in the European Conference on Embolotherapy ET2024 Congress, in Vienna, where we gain Insights and focus on embolization in various areas.

Attending sessions and connecting with partners and healthcare professionals broaden our understanding of user needs and create value for patients. collaboration between different specialties and the importance of clinical evidence was on focus.

It was notable that there is an increasing interest in degradable particles in embolization for various indications and therapeutic areas. Embolotherapy continues to evolve. It promises to become even more precise, evidence-based, and impactful.

If you want to know more about ET2024, click here.

In the photo; Helena Ossmer Thedius, Chief Marketing and Innovation Officer at Magle Group & Franziska Sahm, Medical Affairs Manager at Magle PharmaCept.